Nesfatin-1: A novel inhibitory regulator of food intake and body weight

Obesity Reviews

Volumn 12, Issue 4, 2011, Pages 261-271

  Stengel, A ^a   Goebel, M ^a   Tache Y ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Food intake; Hypothalamus; Nesfatin 1 NUCB2; X A like cells

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ALPHA INTERMEDIN; ANOREXIGENIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARGIPRESSIN; ASTRESSIN B; BINDING PROTEIN; CHOLECYSTOKININ; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOTROPIN RELEASING FACTOR; DNA BINDING PROTEIN; GLUCOSE; GROWTH HORMONE RELEASING FACTOR; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MELANIN CONCENTRATING HORMONE; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NESFATIN 1; NESFATIN 1 RECEPTOR; NESFATIN 2; NESFATIN 3; NEUROPEPTIDE Y; NEUROTENSIN; NEUROTRANSMITTER; NUCLEOBINDIN 2; OXYTOCIN; PEPTIDE HORMONE ANTAGONIST; PROTIRELIN; SOMATOSTATIN; UNCLASSIFIED DRUG; UROCORTIN I;

ANOREXIA; ANTISENSE THERAPY; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CYTOPLASM; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; EPIDEMIC; FEEDING; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; METABOLIC REGULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PARAVENTRICULAR THALAMIC NUCLEUS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SUPRAOPTIC NUCLEUS;

ANIMALS; APPETITE REGULATION; BODY WEIGHT; DISEASE MODELS, ANIMAL; EATING; ENERGY INTAKE; HUMANS; HYPOTHALAMUS; LEPTIN; OBESITY; PEPTIDE HORMONES; RATS; SATIETY RESPONSE; SIGNAL TRANSDUCTION;

EID: 79952785186     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2010.00770.x     Document Type: Article

References (61)

1. Kanai Y, Tanuma S. Purification of a novel B cell growth and differentiation factor associated with lupus syndrome. Immunol Lett 1992; 32: 43-48.
2. Barnikol-Watanabe S, Gross NA, Gotz H, Henkel T, Karabinos A, Kratzin H, Barnikol HU, Hilschmann N. Human protein NEFA, a novel DNA binding/EF-hand/leucine zipper protein. Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biol Chem Hoppe Seyler 1994; 375: 497-512.
3. Lin P, Fischer T, Weiss T, Farquhar MG. Calnuc, an EF-hand Ca(2+) binding protein, specifically interacts with the C-terminal alpha5-helix of G(alpha)i3. Proc Natl Acad Sci USA 2000; 97: 674-679.
4. Miura K, Titani K, Kurosawa Y, Kanai Y. Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure. Biochem Biophys Res Commun 1992; 187: 375-380.
5. Karabinos A, Bhattacharya D, Morys-Wortmann C, Kroll K, Hirschfeld G, Kratzin HD, Barnikol-Watanabe S, Hilschmann N. The divergent domains of the NEFA and nucleobindin proteins are derived from an EF-hand ancestor. Mol Biol Evol 1996; 13: 990-998.
6. Morel-Huaux VM, Pypaert M, Wouters S, Tartakoff AM, Jurgan U, Gevaert K, Courtoy PJ. The calcium-binding protein p54/NEFA is a novel luminal resident of medial Golgi cisternae that traffics independently of mannosidase II. Eur J Cell Biol 2002; 81: 87-100.
7. Oh IS, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-712.
8. Foo K, Brismar H, Broberger C. Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 2008; 156: 563-579.
9. Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Taché Y, Sachs G, Lambrecht NW. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009; 150: 232-238.
10. Gonzalez R, Tiwari A, Unniappan S. Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 2009; 381: 643-648.
11. Goebel M, Stengel A, Wang L, Lambrecht NWG, Taché Y. Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei. Neurosci Lett 2009; 452: 241-246.
12. Brailoiu GC, Dun SL, Brailoiu E, Inan S, Yang J, Chang JK, Dun NJ. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 2007; 148: 5088-5094.
13. Fort P, Salvert D, Hanriot L, Jego S, Shimizu H, Hashimoto K, Mori M, Luppi PH. The satiety molecule nesfatin-1 is co-expressed with melanin concentrating hormone in tuberal hypothalamic neurons of the rat. Neuroscience 2008; 155: 174-181.
14. Kohno D, Nakata M, Maejima Y, Shimizu H, Sedbazar U, Yoshida N, Dezaki K, Onaka T, Mori M, Yada T. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 2008; 149: 1295-1301.
15. Maejima Y, Sedbazar U, Suyama S, Kohno D, Onaka T, Takano E, Yoshida N, Koike M, Uchiyama Y, Fujiwara K, Yashiro T, Horvath TL, Dietrich MO, Tanaka S, Dezaki K, Oh IS, Hashimoto K, Shimizu H, Nakata M, Mori M, Yada T. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab 2009; 10: 355-365.
16. Inhoff T, Stengel A, Peter L, Goebel M, Taché Y, Bannert N, Wiedenmann B, Klapp BF, Mönnikes H, Kobelt P. Novel insight in distribution of nesfatin-1 and phospho-mTOR in the arcuate nucleus of the hypothalamus of rats. Peptides 2010; 31: 257-262.
17. Okere B, Xu L, Roubos EW, Sonetti D, Kozicz T. Restraint stress alters the secretory activity of neurons co-expressing urocortin-1, cocaine- and amphetamine-regulated transcript peptide and nesfatin-1 in the mouse Edinger-Westphal nucleus. Brain Res 2010; 1317C: 92-99.
18. Taniguchi N, Taniura H, Niinobe M, Takayama C, Tominaga-Yoshino K, Ogura A, Yoshikawa K. The postmitotic growth suppressor necdin interacts with a calcium-binding protein (NEFA) in neuronal cytoplasm. J Biol Chem 2000; 275: 31674-31681.
19. Kanai Y, Miura K, Uehara T, Amagai M, Takeda O, Tanuma S, Kurosawa Y. Natural occurrence of Nuc in the sera of autoimmune-prone MRL/lpr mice. Biochem Biophys Res Commun 1993; 196: 729-736.
20. Bustos G, Abarca J, Campusano J, Bustos V, Noriega V, Aliaga E. Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain. Brain Res Brain Res Rev 2004; 47: 126-144.
21. Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 2004; 25: 150-176.
22. Stengel A, Goebel M, Wang L, Rivier J, Kobelt P, Mönnikes H, Lambrecht NW, Taché Y. Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor2 receptor. Endocrinology 2009; 150: 4911-4919.
23. Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol 2009; 297: R330-R336.
24. Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005; 128: 175-191.
25. Price CJ, Samson WK, Ferguson AV. Nesfatin-1 inhibits NPY neurons in the arcuate nucleus. Brain Res 2008; 1230: 99-106.
26. Shimizu H, Arima H, Ozawa Y, Watanabe M, Banno R, Sugimura Y, Ozaki N, Nagasaki H, Oiso Y. Glucocorticoids increase NPY gene expression in the arcuate nucleus by inhibiting mTOR signaling in rat hypothalamic organotypic cultures. Peptides 2010; 31: 145-149.
27. Yosten GL, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1642-1647.
28. Zorrilla EP, Taché Y, Koob GF. Nibbling at CRF receptor control of feeding and gastrocolonic motility. Trends Pharmacol Sci 2003; 24: 421-427.
29. Fekete EM, Inoue K, Zhao Y, Rivier JE, Vale WW, Szucs A, Koob GF, Zorrilla EP. Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval. Neuropsychopharmacology 2007; 32: 1052-1068.
30. Rivier J, Gulyas J, Kirby D, Low W, Perrin MH, Kunitake K, DiGruccio M, Vaughan J, Reubi JC, Waser B, Koerber SC, Martinez V, Wang L, Taché Y, Vale W. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 2002; 45: 4737-4747.
31. Lu XY, Barsh GS, Akil H, Watson SJ. Interaction between alpha-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. J Neurosci 2003; 23: 7863-7872.
32. Kawashima S, Sakihara S, Kageyama K, Nigawara T, Suda T. Corticotropin-releasing factor (CRF) is involved in the acute anorexic effect of a-melanocyte-stimulating hormone: a study using CRF-deficient mice. Peptides 2008; 29: 2169-2174.
33. Xu L, Bloem B, Gaszner B, Roubos EW, Kozicz LT. Sex-specific effects of fasting on Urocortin 1, Cocaine- and Amphetamine-Regulated Transcript peptide and Nesfatin-1 expression in the rat Edinger-Westphal nucleus. Neuroscience 2009; 162: 1141-1149.
34. Nonogaki K, Ohba Y, Sumii M, Oka Y. Serotonin systems upregulate the expression of hypothalamic NUCB2 via 5-HT2C receptors and induce anorexia via a leptin-independent pathway in mice. Biochem Biophys Res Commun 2008; 372: 186-190.
35. Noetzel S, Stengel A, Inhoff T, Goebel M, Wisser AS, Bannert N, Wiedenmann B, Klapp BF, Taché Y, Mönnikes H, Kobelt P. CCK-8S activates c-Fos in a dose-dependent manner in nesfatin-1 immunoreactive neurons in the paraventricular nucleus of the hypothalamus and in the nucleus of the solitary tract of the brainstem. Regul Pept 2009; 157: 84-91.
36. Barquist E, Bonaz B, Martinez V, Rivier J, Zinner MJ, Taché Y. Neuronal pathways involved in abdominal surgery-induced gastric ileus in rats. Am J Physiol 1996; 270: R888-R894.
37. Stengel A, Goebel M, Wang L, Taché Y. Abdominal surgery activates nesfatin-1 immunoreactive brain nuclei in rats. Peptides 2010; 31: 263-270.
38. Bonnet MS, Pecchi E, Trouslard J, Jean A, Dallaporta M, Troadec JD. Central nesfatin-1 expressing neurons are sensitive to peripheral inflammatory stimulus. J Neuroinflammation 2009; 6: 27.
39. Herman JP, Cullinan WE. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 1997; 20: 78-84.
40. Dayas CV, Buller KM, Day TA. Neuroendocrine responses to an emotional stressor: evidence for involvement of the medial but not the central amygdala. Eur J Neurosci 1999; 11: 2312-2322.
41. Goebel M, Stengel A, Wang L, Taché Y. Restraint stress activates nesfatin-1-immunoreactive brain nuclei in rats. Brain Res 2009; 1300: 114-124.
42. Merali Z, Cayer C, Kent P, Anisman H. Nesfatin-1 increases anxiety- and fear-related behaviors in the rat. Psychopharmacology (Berl) 2008; 201: 115-123.
43. Kalin NH, Takahashi LK. Fear-motivated behavior induced by prior shock experience is mediated by corticotropin-releasing hormone systems. Brain Res 1990; 509: 80-84.
44. Heinrichs SC, Menzaghi F, Merlo Pich E, Britton KT, Koob GF. The role of CRF in behavioral aspects of stress. Ann N Y Acad Sci 1995; 771: 92-104.
45. Spina MG, Merlo-Pich E, Akwa Y, Balducci C, Basso AM, Zorrilla EP, Britton KT, Rivier J, Vale WW, Koob GF. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology (Berl) 2002; 160: 113-121.
46. Pelleymounter MA, Joppa M, Ling N, Foster AC. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 2004; 25: 659-666.
47. Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci 1992; 15: 353-375.
48. Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 2007; 28: 2223-2228.
49. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007; 28: 2372-2381.
50. Gardiner JV, Jayasena CN, Bloom SR. Gut hormones: a weight off your mind. J Neuroendocrinol 2008; 20: 834-841.
51. Foo KS, Brauner H, Ostenson CG, Broberger C. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 2010; 204: 255-263.
52. Shimizu H, Oh IS, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, Okada S, Yamada M, Yada T, Mori M. Peripheral administration of nesfatin-1 reduces food intake in mice: The leptin-independent mechanism. Endocrinology 2009; 150: 662-671.
53. Shimizu H, Ohsaki A, Oh IS, Okada S, Mori M. A new anorexigenic protein, nesfatin-1. Peptides 2009; 30: 995-998.
54. Iwasaki Y, Nakabayashi H, Kakei M, Shimizu H, Mori M, Yada T. Nesfatin-1 evokes Ca2+ signaling in isolated vagal afferent neurons via Ca2+ influx through N-type channels. Biochem Biophys Res Commun 2009; 390: 958-962.
55. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 2010; 159: 72-77.
56. Iguchi H, Ikeda Y, Okamura M, Tanaka T, Urashima Y, Ohguchi H, Takayasu S, Kojima N, Iwasaki S, Ohashi R, Jiang S, Hasegawa G, Ioka RX, Magoori K, Sumi K, Maejima T, Uchida A, Naito M, Osborne TF, Yanagisawa M, Yamamoto TT, Kodama T, Sakai J. SOX6 attenuates glucose-stimulated insulin secretion by repressing PDX1 transcriptional activity and is down-regulated in hyperinsulinemic obese mice. J Biol Chem 2005; 280: 37669-37680.
57. Abdel-Halim SM, Guenifi A, Luthman H, Grill V, Efendic S, Ostenson CG. Impact of diabetic inheritance on glucose tolerance and insulin secretion in spontaneously diabetic GK-Wistar rats. Diabetes 1994; 43: 281-288.
58. Ostenson CG, Khan A, Abdel-Halim SM, Guenifi A, Suzuki K, Goto Y, Efendic S. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia 1993; 36: 3-8.
59. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391: 1039-1042.
60. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537-556.
61. Shimizu H, Oh IS, Okada S, Mori M. Nesfatin-1: an overview and future clinical application. Endocr J 2009; 56: 537-543.